Documentdetail
ID kaart

oai:arXiv.org:2408.08193

Onderwerp
Computer Science - Human-Computer ...
Auteur
Gualano, Ria J. Jiang, Lucy Zhang, Kexin Shende, Tanisha Won, Andrea Stevenson Azenkot, Shiri
Categorie

Computer Science

Jaar

2024

vermelding datum

21-08-2024

Trefwoorden
embodied people disabilities vr
Metriek

Beschrijving

With the increasing adoption of social virtual reality (VR), it is critical to design inclusive avatars.

While researchers have investigated how and why blind and d/Deaf people wish to disclose their disabilities in VR, little is known about the preferences of many others with invisible disabilities (e.g., ADHD, dyslexia, chronic conditions).

We filled this gap by interviewing 15 participants, each with one to three invisible disabilities, who represented 22 different invisible disabilities in total.

We found that invisibly disabled people approached avatar-based disclosure through contextualized considerations informed by their prior experiences.

For example, some wished to use VR's embodied affordances, such as facial expressions and body language, to dynamically represent their energy level or willingness to engage with others, while others preferred not to disclose their disability identity in any context.

We define a binary framework for embodied invisible disability expression (public and private) and discuss three disclosure patterns (Activists, Non-Disclosers, and Situational Disclosers) to inform the design of future inclusive VR experiences.

;Comment: To appear at ASSETS 2024

Gualano, Ria J.,Jiang, Lucy,Zhang, Kexin,Shende, Tanisha,Won, Andrea Stevenson,Azenkot, Shiri, 2024, "I Try to Represent Myself as I Am": Self-Presentation Preferences of People with Invisible Disabilities through Embodied Social VR Avatars

Document

Openen

Delen

Bron

Artikelen aanbevolen door ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw